Why the study?
Preoperative platelet function tests reduce re-intervention and transfusion in CABG, but the predictive value and justification for routine preoperative multiple electrode aggregometry needed investigation.
Does preoperative platelet function testing predict severe bleeding and transfusion requirements in patients undergoing elective CABG?
Does preoperative platelet function testing predict severe bleeding and transfusion requirements in patients undergoing elective CABG?
Preoperative platelet function testing using ASPI and ADPHS significantly predicts severe postoperative bleeding and transfusion requirements in elective CABG patients, suggesting utility in guiding perioperative management.
Answers are grounded in this paper and cite their sources.
Preoperative aggregometry may predict bleeding risk in CABG; leaves open whether routine testing improves outcomes.
BACKGROUND: Preoperative use of platelet function tests contributes to the decrease of re-intervention rate due to bleeding and the necessity of transfusion in coronary artery bypass grafting (CABG) patients. The aim was to investigate the predictive value and to justify routine preoperative use of multiple electrode aggregometry in these patients. METHODS: A prospective observational trial which included 416 consecutive patients subjected to elective isolated CABG was conducted. The Multiplate® test was used to assess platelet function. Platelet function test results, postoperative blood loss, and transfusion requirements were compared between high and low bleeding risk patients. Receiver operating characteristic analysis was performed to assess the sensitivity and specificity of the arachidonic acid (ASPI) and adenosine di-phosphate high sensitive (ADPHS) tests. RESULTS: ADPHS and ASPI test results significantly predicted total bleeding > 1000 ml (AUC, 0.685, p < .001; 0.695, p = .039). Sensitivity and specificity were 62.9% and 40.0%, for ADPHS ≤602, and 70.8% and 41.8%, for ASPI ≤ 453. The sensitivity and specificity of cut-off values recommended by the manufacturer were 84.2% and 40.0% for ADPHS ≤ 500, while for ASPI < 600 the values were 54.7% and 62.2%. More platelets and cryoprecipitate were transfused in patients with ADPHS ≤ 602.5 (p < .001; p = .035). Patients with ADPHS ≤ 500 had a higher rate of red blood count, platelet and cryoprecipitate transfusion (p<.001p<.001; p = .013). The manufacturer's ASPI test cut-off values showed no statistically significant prediction for a higher transfusion rate. CONCLUSION: Preoperative platelet function tests should be conducted systematically for all elective CABG patients who were on dual antiplatelet therapy after adjusting test cut-off values for each population.
No takes yet. Share an insight, caveat, or question.
Matković et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: